BioSpace News Archive

MediView XR, Inc., a leading clinical augmented reality med-tech company, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its XR90 augmented reality-based surgical visualization and navigation platform.

Advent Therapeutics, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Designation (RPDD) for its vitamin A metabolic and reparative respiratory drugs for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants.

BioSig Technologies, Inc. today announced that its subsidiary BioSig AI Sciences, Inc. (BAIS) was selected to join NVIDIA Inception, a program designed to partner with companies revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.

Collegium Pharmaceutical, Inc. today announced that it will report second quarter 2023 financial results after the market closes on Thursday, August 3, 2023.

Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie’s disease), a non-interventional registry of up to 1,000 patients with Peyronie’s disease (PD).

Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team.

Motus GI Holdings, Inc. announced that Banner Desert Medical Center has purchased and initiated the implementation of the Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures for patients who present with inadequate bowel preparation.

Recludix Pharma today announced that the company has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases.

Longeveron Inc. announced today the appointment of Lisa Locklear as Executive Vice President and Chief Financial Officer.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.